TOVX
Theriva Biologics, Inc.Company with tickers: TOVX
CIK
894158
CUSIP
87164U508
Shares Outstanding
45,892,668
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $300,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $2,427,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Research & Development | $355,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Operating Income | $-2,127,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Net Income | — | ||||
| EPS (Basic) | $-0.05 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Diluted) | $-0.05 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |